Compounds that inhibit MCL-1 protein


Ontology type: sgo:Patent     


Patent Info

DATE

2020-11-17T00:00

AUTHORS

BROWN SEAN P , LI YUNXIAO , LIZARZABURU MIKE ELIAS , LUCAS BRIAN S , PARAS NICK A , TAYGERLY JOSHUA , VIMOLRATANA MARC , WANG XIANGHONG , YU MING , ZANCANELLA MANUEL , ZHU LIUSHENG , GONZALEZ BUENROSTRO ANA , LI ZHIHONG

ABSTRACT

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. More... »

Related SciGraph Publications

  • 2008-12. BCL-2 family antagonists for cancer therapy in NATURE REVIEWS DRUG DISCOVERY
  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0305", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "BROWN SEAN P", 
            "type": "Person"
          }, 
          {
            "name": "LI YUNXIAO", 
            "type": "Person"
          }, 
          {
            "name": "LIZARZABURU MIKE ELIAS", 
            "type": "Person"
          }, 
          {
            "name": "LUCAS BRIAN S", 
            "type": "Person"
          }, 
          {
            "name": "PARAS NICK A", 
            "type": "Person"
          }, 
          {
            "name": "TAYGERLY JOSHUA", 
            "type": "Person"
          }, 
          {
            "name": "VIMOLRATANA MARC", 
            "type": "Person"
          }, 
          {
            "name": "WANG XIANGHONG", 
            "type": "Person"
          }, 
          {
            "name": "YU MING", 
            "type": "Person"
          }, 
          {
            "name": "ZANCANELLA MANUEL", 
            "type": "Person"
          }, 
          {
            "name": "ZHU LIUSHENG", 
            "type": "Person"
          }, 
          {
            "name": "GONZALEZ BUENROSTRO ANA", 
            "type": "Person"
          }, 
          {
            "name": "LI ZHIHONG", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrd2658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030857223", 
              "https://doi.org/10.1038/nrd2658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2020-11-17T00:00", 
        "description": "

    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

    \n

    \"embedded
    \nand pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.\n

    ", "endDate": "2035-08-28", "id": "sg:patent.US-10836779-B2", "name": "Compounds that inhibit MCL-1 protein", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.417886.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-10836779-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-10-01T07:03", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/patent/patent_37.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-10836779-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-10836779-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-10836779-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-10836779-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    82 TRIPLES      15 PREDICATES      18 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-10836779-B2 schema:about anzsrc-for:03
    2 anzsrc-for:0305
    3 schema:author N361055063d2d4aaaa35a8c9d7e530720
    4 schema:citation sg:pub.10.1007/s00018-008-8637-6
    5 sg:pub.10.1038/nrd2658
    6 schema:datePublished 2020-11-17T00:00
    7 schema:description <p id="p-0001" num="0000">Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="41.99mm" wi="68.58mm" file="US10836779-20201117-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif" orientation="portrait" inline="no"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US10836779-20201117-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US10836779-20201117-C00001.MOL"/></attachments></chemistry><br/> and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. </p>
    8 schema:endDate 2035-08-28
    9 schema:name Compounds that inhibit MCL-1 protein
    10 schema:recipient grid-institutes:grid.417886.4
    11 schema:sameAs https://app.dimensions.ai/details/patent/US-10836779-B2
    12 schema:sdDatePublished 2022-10-01T07:03
    13 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    14 schema:sdPublisher Nc130d5551a0e49b2b90332e7999e4d0d
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset patents
    17 rdf:type sgo:Patent
    18 N0120e95b361d4208999f0f40a3dfa37e schema:name BROWN SEAN P
    19 rdf:type schema:Person
    20 N1826cfe2823645ed8dc412a3962b4a66 schema:name GONZALEZ BUENROSTRO ANA
    21 rdf:type schema:Person
    22 N259c598855c445eba6583c7795cef81e rdf:first N85ff3463beff493d97f5728eb35a3c59
    23 rdf:rest N8ad0300308ce44438171f8bcac2c1a6d
    24 N2d3d15e0b4ad43408d15deec97ff69c7 schema:name TAYGERLY JOSHUA
    25 rdf:type schema:Person
    26 N33c4a83644ca487a9222b481aaab6f6e rdf:first N1826cfe2823645ed8dc412a3962b4a66
    27 rdf:rest Ndd395b65043249968a40cd31e025fe08
    28 N361055063d2d4aaaa35a8c9d7e530720 rdf:first N0120e95b361d4208999f0f40a3dfa37e
    29 rdf:rest N6a105c3f5bec4e20abc102dad1631225
    30 N56d0178dd6814bedbc4606b3676b9c1c schema:name LI YUNXIAO
    31 rdf:type schema:Person
    32 N5722e878d2ff4629b85a99f3586ca783 schema:name LIZARZABURU MIKE ELIAS
    33 rdf:type schema:Person
    34 N5b9d3f4822cc46f69171beef86548339 rdf:first N6f916b1d679e4bbcb22dc26ac97a1657
    35 rdf:rest N33c4a83644ca487a9222b481aaab6f6e
    36 N6042a9b420454f6fab136ab5c1bb429f rdf:first N5722e878d2ff4629b85a99f3586ca783
    37 rdf:rest N8d470e801c5742ae83a4ef527673c2b2
    38 N69a33aed474647cbb39146633a273e7e schema:name LUCAS BRIAN S
    39 rdf:type schema:Person
    40 N6a105c3f5bec4e20abc102dad1631225 rdf:first N56d0178dd6814bedbc4606b3676b9c1c
    41 rdf:rest N6042a9b420454f6fab136ab5c1bb429f
    42 N6f916b1d679e4bbcb22dc26ac97a1657 schema:name ZHU LIUSHENG
    43 rdf:type schema:Person
    44 N7876746ba86a45ec80ab930040f0bf4c rdf:first Nc1444bd3190b4707bfe141d0240a2e52
    45 rdf:rest N7bfc3c7d5b1d47abbeea25b2f73aab8c
    46 N7bfc3c7d5b1d47abbeea25b2f73aab8c rdf:first Nc412c41ae04d4152ad5411dc7850c085
    47 rdf:rest N259c598855c445eba6583c7795cef81e
    48 N85ff3463beff493d97f5728eb35a3c59 schema:name YU MING
    49 rdf:type schema:Person
    50 N8ad0300308ce44438171f8bcac2c1a6d rdf:first Nb6bdc1112e4641db8685e502a7458b49
    51 rdf:rest N5b9d3f4822cc46f69171beef86548339
    52 N8d470e801c5742ae83a4ef527673c2b2 rdf:first N69a33aed474647cbb39146633a273e7e
    53 rdf:rest Ndd8d26ef9c4a471a9f66ef34992c629b
    54 Nb6bdc1112e4641db8685e502a7458b49 schema:name ZANCANELLA MANUEL
    55 rdf:type schema:Person
    56 Nc130d5551a0e49b2b90332e7999e4d0d schema:name Springer Nature - SN SciGraph project
    57 rdf:type schema:Organization
    58 Nc1444bd3190b4707bfe141d0240a2e52 schema:name VIMOLRATANA MARC
    59 rdf:type schema:Person
    60 Nc412c41ae04d4152ad5411dc7850c085 schema:name WANG XIANGHONG
    61 rdf:type schema:Person
    62 Nd2df4ca5559e440c86cced227bd8d748 schema:name PARAS NICK A
    63 rdf:type schema:Person
    64 Ndc7d02125176403c8314acac86fa3896 rdf:first N2d3d15e0b4ad43408d15deec97ff69c7
    65 rdf:rest N7876746ba86a45ec80ab930040f0bf4c
    66 Ndd395b65043249968a40cd31e025fe08 rdf:first Ndf7c705c85414f339e029a447c0d6130
    67 rdf:rest rdf:nil
    68 Ndd8d26ef9c4a471a9f66ef34992c629b rdf:first Nd2df4ca5559e440c86cced227bd8d748
    69 rdf:rest Ndc7d02125176403c8314acac86fa3896
    70 Ndf7c705c85414f339e029a447c0d6130 schema:name LI ZHIHONG
    71 rdf:type schema:Person
    72 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
    73 rdf:type schema:DefinedTerm
    74 anzsrc-for:0305 schema:inDefinedTermSet anzsrc-for:
    75 rdf:type schema:DefinedTerm
    76 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    77 https://doi.org/10.1007/s00018-008-8637-6
    78 rdf:type schema:CreativeWork
    79 sg:pub.10.1038/nrd2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030857223
    80 https://doi.org/10.1038/nrd2658
    81 rdf:type schema:CreativeWork
    82 grid-institutes:grid.417886.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...